Results 141 to 150 of about 983 (198)

Behandlung einer symptomatischen Hypersomnie mit Solriamfetol

Nervenheilkunde, 2021
ZUSAMMENFASSUNGEs wird der Fall eines 34 Jahre alten Patienten berichtet, der nach einer Epstein-Barr-Virus-Infektion eine symptomatische Hypersomnie entwickelt hat. Diese Hypersomnie konnte mit konventionellen Substanzen nicht befriedigend gebessert werden. Unter Solriamfetol kam es zu einer signifikanten Besserung der exzessiven Tagesschläfrigkeit.
Susan Wald, Stefan Evers
openaire   +1 more source

Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany

Sleep Medicine, 2023
BACKGROUND Excessive daytime sleepiness (EDS) is a core narcolepsy symptom, for which solriamfetol (Sunosi®) was recently approved in the European Union.
Yaroslav Winter, Ulf Kallweit
exaly   +2 more sources

Solriamfetol improves symptoms in myalgic encephalomyelitis/chronic fatigue

The Brown University Psychopharmacology Update
openaire   +2 more sources

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Sleep Medicine
BACKGROUND Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). The current study aims to evaluate effects of solriamfetol
Jiu-cheng Shen, K. Guo, Jing Wang, Zhijun Wang, Shiyuan Gao, Qiao-jun Wang, Fei Han, Weijia Zhang, Xiang Li, Hui Ye, Rui Chen   +10 more
semanticscholar   +1 more source

Solriamfetol: First Global Approval

Drugs, 2019
Solriamfetol (Sunosi™) is an orally active, selective dopamine and norepinephrine reuptake inhibitor that was recently approved in the USA as a treatment for excessive daytime sleepiness (hypersomnia) associated with narcolepsy and obstructive sleep apnoea (OSA).
openaire   +2 more sources

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment

Journal of Psychopharmacology
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a long-term illness with no treatment options that address the disease directly.
Joel L. Young, Richard N. Powell, Anna Powell, Lisa L M Welling, Lauren Granata, Jaime Saal   +5 more
semanticscholar   +1 more source

0864 Assessing Patient Preference of Solriamfetol Following Usage of Modafinil/Armodafinil: A Single Center Retrospective Analysis

Sleep
Wakefulness promoting agents (WPA) are a class of drugs typically used for patients suffering from excessive daytime sleepiness to improve alertness.
Grace Martin, Prisha Patel, Pratik Pohuja, S. Meskill, G. Meskill   +4 more
semanticscholar   +1 more source

0881 Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Early Morning Shift Work Disorder

Sleep
Shiftwork is common and in 10-43% of individuals it leads to a diagnosis of shift work disorder (SWD), characterized by excessive sleepiness accompanied by reduced sleep duration and/or insomnia.
Kirsi-Marja Zitting, Katherine Gilmore, B. Lockyer, Eileen Leary, Stuart Quan, Wei Wang, Nicolas Issa, Jonathan S. Williams, Jeanne Duffy, C. Czeisler   +9 more
semanticscholar   +1 more source

0784 Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study

Sleep
Patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) show deficits in cognitive domains including alertness, attention, executive function and decision-making.
Y. Winter, Graham M L Eglit, S. Floam, U. Kallweit   +3 more
semanticscholar   +1 more source

0786 Real-World Use of Solriamfetol for Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea in the US

Sleep
Excessive daytime sleepiness (EDS) is a vital and often overlooked patient-centered outcome in obstructive sleep apnea (OSA) and is associated with worsened health and economic outcomes. Solriamfetol (Sunosi®), a wake-promoting agent (WPA) approved
Yang Zhao, Anh Thu Tran, H. Varker, S. Floam   +3 more
semanticscholar   +1 more source